Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
17 stopped studies mapped to Papillary Adenocarcinoma and descendants · 82% state a reason
Over the 17 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05575440 | Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer | — | terminated | Oct 12, 2022 | Mayo Clinic | Slow accrual; lack of eligible study participants | Enrollment / accrual |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory…(DUTHY) | Phase 2 | terminated | Nov 27, 2018 | Grupo Espanol de Tumores Neuroendocrinos | In compliance with current legislation applicable to Clinical Trials, following the instructions of… | Other (stated, no rule matched) |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | N/A | terminated | Aug 20, 2021 | Nantes University Hospital | end-of-study visit not completed within the protocol timeframe | Other (stated, no rule matched) |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid… | Phase 1 | terminated | Mar 19, 2018 | AHS Cancer Control Alberta | Lack of Accrual | Enrollment / accrual |
| NCT05003856 | Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule | N/A | terminated | Aug 12, 2021 | M.D. Anderson Cancer Center | Administrativley Complete, 75%\<Participants | Other (stated, no rule matched) |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell… | Phase 2 | withdrawn | Oct 26, 2020 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive… | Phase 2 | terminated | Apr 23, 2018 | Emory University | Study has been abandoned for lack of accrual | Enrollment / accrual |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell… | Phase 1 | terminated | Jul 20, 2016 | Celldex Therapeutics | Development of CDX-014 discontinued | Other (stated, no rule matched) |
| NCT01974284 | Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | N/A | terminated | Nov 1, 2013 | Yale University | Lack of patient enrollment | Enrollment / accrual |
| NCT01754519 | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer… | Phase 2 | terminated | Dec 21, 2012 | Roswell Park Cancer Institute | IDE not submitted | Other (stated, no rule matched) |
| NCT00053235 | Research Study in Patients With Advanced Ovarian Epithelial Cancer | — | withdrawn | Jan 28, 2003 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally… | Phase 2 | terminated | Nov 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials